0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover211.98%IV-46.51%PremiumMay 16, 2025Expiry Date10.87Intrinsic Value100Multiplier16DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9499Delta0.0100Gamma2.10Leverage Ratio-0.0344Theta0.0048Rho1.99Eff Leverage0.0050Vega
Vera Therapeutics Stock Discussion
Major Milestone: 431 Patients Enrolled in Vera's Groundbreaking IgAN Treatment Trial
Can Vera's Breakthrough IgAN Therapy Disrupt the $5B Kidney Disease Market? Phase 3 Results Coming Q2 2025
📊⚡️📊
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
No comment yet